Simple blood test could tell doctors which cancer patients will respond to immunotherapy
NCT ID NCT07246759
Summary
This study aims to develop a blood test that predicts whether cancer patients will benefit from immunotherapy drugs. Researchers will analyze blood samples from 600 patients with lung cancer, melanoma, breast cancer, kidney cancer, or head/neck cancer before they start treatment. The test measures specific immune cells to help doctors determine if immunotherapy is likely to work for each patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Heidelberg University Hospital
Heidelberg, 69120, Germany
Contact Email: •••••@•••••
Contact
-
Intituto Europeo di Oncologia SRL
Milan, 20121, Italy
Contact
Contact Email: •••••@•••••
-
Virgen Macarena University Hospital - Servicio Andaluz de Salud
Seville, 41071, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.